Supportive Care in Cancer

, Volume 14, Issue 6, pp 566–572

Amifostine in the management of radiation-induced and chemo-induced mucositis

Authors

    • Department of Radiation OncologyCentre Antoine-Lacassagne
  • Mark M. Schubert
    • Department of Oral MedicineUniversity of Washington, Oral Medicine Service, Seattle Cancer Care Alliance
  • Rajesh V. Lalla
    • Department of Oral Health and Diagnostic Sciences MC1605University of Connecticut Health Center
  • Dorothy Keefe
    • Department of MedicineUniversity of Adelaide
Review Article

DOI: 10.1007/s00520-006-0047-4

Cite this article as:
Bensadoun, R., Schubert, M.M., Lalla, R.V. et al. Support Care Cancer (2006) 14: 566. doi:10.1007/s00520-006-0047-4

Abstract

Introduction

Mucositis is a significant complication of cancer therapy, with important clinical and economic implications. In June 2005, the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) conducted an evidence-based update review of the literature on mucositis. The goal of this literature review is to update previously published guidelines for the management of mucositis.

Results

This article reports the findings of the subgroup charged with reviewing the literature related to amifostine.

Keywords

AmifostineMucositisRadiotheraphyChemotheraphy

Copyright information

© Springer-Verlag 2006